Physician profile
Sheba M Joseph
NPI 1104082908
$16,020.23
in general payments reported to CMS, 2019-2025
51 companies · $1,998 in 2025
The $1,998 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,028 · 2020: $1,690 · 2021: $2,701 · 2022: $2,754 · 2023: $2,557 · 2024: $2,292 · 2025: $1,998.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,847.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,847.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,808.15 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,800.34 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $1,614.20 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $1,481.23 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $1,431.78 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $970.79 | 2019-2025 | Spravato, Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $759.29 | 2019-2024 | Jardiance, Ofev |
| Takeda Pharmaceuticals U.S.A., INC. | $715.85 | 2019-2025 | Trintellix |
| Pfizer INC. | $684.81 | 2019-2025 | |
| Amgen INC. | $683.15 | 2019-2025 | Otezla, Repatha, Evenity |
| Abbott Laboratories | $542.70 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $492.70 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $330.10 | 2019-2025 | Xifaxan |
| Exact Sciences Corporation | $317.33 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $268.02 | 2022-2025 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheba Joseph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.